AstraZeneca AZN and Ionis Pharmaceuticals IONS announced that the Committee for Medicinal Products for Human Use (CHMP) has ...

The opinion rejects granting conditional marketing authorization to AB Science’s masitinib as an oral add-on treatment for ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...

Astellas has announced the withdrawal of its MAA for ACP from the EMA to treat geographic atrophy (GA) secondary to AMD.

AstraZeneca and Ionis are collaborating on the commercialisation of the drug following a December 2021 global agreement.

The CHMP of the regulatory body in the EU adopts a positive opinion recommending the approval of Novo Nordisk's Alhemo for ...

Four months after the Committee for Medicinal Products for Human Use (CHMP) rejected Apellis’ GA application for Syfovre for a second time, Astellas has withdrawn its application for the ...

A European Medicines Agency committee has recommended that concizumab be approved in the EU to treat hemophilia A or B with ...

Japanese drugmaker Astellas Pharma revealed it has decided to withdraw its marketing authorization application from the ...

Astellas Pharma Inc. has withdrawn its marketing authorization application from the EMA for its avacincaptad pegol intravitreal solution for the treatment of geographic atrophy secondary to ...

EMA committee recommends extended authorization for BeiGene’s Tevimbra to treat gastric or gastroesophageal junction cancer & ESCC: San Mateo, California Wednesday, October 23, ...

AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union as an add-on treatment for adults with eosinophilic granulomatosis ...